In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis

In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02852850

Enrollment

Registered

2016-08-02

Start date

2016-01-31

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with active ulcerative colitis will receive infliximab antibody therapy.

Exclusion criteria

* Patients with impaired blood clotting. * Patients with short bowel syndrome. * Patients during the pregnancy and lactation period. * Patients received enema therapy within 1 month before inclusion in the study, or had anti-TNF therapy within the last 12 months. * Patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit. * Patients with moderate to severe heart failure, active tuberculosis or acute infections.

Design outcomes

Primary

Measure	Time frame
The number of specific fluorescence signal of mTNF+ cells in patients with UC	30 months

Countries

China

Contacts

Primary ContactYanqing Li, PhD. MD.

liyanqing@sdu.edu.cn86-531-82169236

Outcome results